


October 24, 2024

Cain Brothers Industry Insights

Healthcare Market Report



Banker commentary:

Innovation and Expertise at Cain Brothers 2024 Private Company Healthcare Conference

Banker Commentary

Contents

- Banker Commentary
- M&A Activity
- Private Placements
- Equity Capital Markets
- Public Equity Market Activity and Indices
- High Grade, High Yield & Leveraged Loans
- Public Finance Market
- Relevant News
- Recent Cain Brothers Transactions

Innovation and Expertise at Cain Brothers 2024 Private Company Healthcare Conference

Commentary by Keith Hollihan, 4sight Health

Cain Brothers, a division of KeyBanc Capital Markets, convened its 11th Annual Private Company Healthcare Conference on October 16 and 17, last week at the New York Lotte Palace Hotel. The conference featured:

- Over 500 top leaders from healthcare companies, private equity, venture capital, and healthcare-related corporations
- 54 participating companies, spanning nearly all sectors of the healthcare economy, reflecting the breadth and depth of Cain Brothers' industry coverage and relationships
- · 2 keynote panel presentations on urgent industry topics
- Over 600 one-on-one investor meetings with company leaders

In his opening remarks, the head of Cain Brothers, **Wyatt Ritchie**, observed that when the firm was founded 42 years ago, most investment banking firms were generalists but Jim and Dan Cain believed that exclusive coverage of a single industry would yield better advice and counsel. Today, as we exit a period of cheap capital, success in healthcare markets requires the kind of expertise, perspective and relationships that such specialization brings. Cain Brothers is uniquely positioned to advise companies, organizations and investors looking to create a more efficient industry that meets the difficult challenges and issues of our era.

One of those challenges is runaway costs across the system as a whole and for consumers in particular. As the Wall Street Journal recently <u>reported</u>, employer health insurance costs have risen 7% for the second year in a row, an unprecedented rate that has added more than \$3000 to average family premiums, which now amount to around \$25,500 per year. As private equity panelist Anna Haghgooie offered a few minutes later, "We're close to the tipping point. Every family is buying a small car each year and getting no value for it as they pay their insurance premiums." Such issues were top-of-mind in two stimulating panel discussions that brought attendees and thought leaders together.

Restoring the Roar: Private Equity's Insights on the Recovering M&A Markets and Unique Investment Perspectives for 2025

As Wyatt noted, private equity has been blasted recently for driving up costs rather than generating efficiencies. Industry <u>reports</u> like Avalere's recent review of physician-driven Medicare expenditures indicate that such criticisms may be simplistic. Data-driven perspectives are needed to capture the impact of private equity's longer-term investment horizon.

The first panel aimed to provide that reasoned view. Featuring Anna Haghgooie, Managing Director at Valtruis and Operating Partner at Welsh, Carson, Anderson & Stowe, Ben Edmands, Managing Director and Co-Founder at Consonance Capital, and Jeff Abramoff, Partner at Court Street Capital Partners, and facilitated by Cain Brothers Managing Director, Matt Margulies, the discussion spanned a range of important themes including:



continued...

- · Progress and challenges in value-based care
- PBM and pharmacy market dynamics
- Opportunities in pediatric home health
- Challenges in provider investments
- Stakeholders driving change including employers, consumers and Medicare Advantage competition

In speaking about what makes a provider business investable today, Ben described the shifting focus away from simple rollups that expand scale and infrastructure to "models that are using technology, integration and innovation to actually deliver better outcomes and drive efficiencies."

Jeff Abramoff agreed that the days of expecting multiple arbitrage are gone. Today, integration must go beyond the table stakes of centralizing back offices and building a brand. Instead, "What can we do once we have one platform, what can we do with the data, what can we do with the doctors themselves to improve their practice?"

Anna Haghgooie added that providers need "models to get past encounter-based reimbursement because then you have the flexibility to use technology to bring down the cost curve and create a path to contracting differently."

Disruptive Healthcare Purchasing by Self-Insured Employers

The conference ended with a panel on opportunities in the self-insured employer market, featuring the leaders of two innovative companies, Donald Trigg, CEO of <u>apree health</u> and Glenn Tullman, CEO of <u>Transcarent</u>. The discussion was facilitated by Cain Brothers' thought-leadership partner Dave Johnson, CEO of 4sight Health, whose new book with Paul Kusserow, <u>The Coming Healthcare Revolution: 10 Forces that Will Cure America's Health Crisis</u>, features both companies as case studies.

As Dave noted in his introduction of Donald and Glenn, self-insured employers have long paid a premium for commodity healthcare services without receiving premium value. apree and Transcarent are working in different ways to improve the experience and cost of healthcare.

Glen described the challenge bluntly: "Employers have simply run out of money and patients can't pay more. Starbucks spends more on healthcare than they do buying coffee." Moreover, consumers across all demographics, regions, and political views, see healthcare as more confusing and complex than ever. Transcarent's solution is to empower consumers with a smart phone-based platform and an Al "wayfinding" interface that dramatically enhances ease of access to a suite of services while simplifying the employer's ability to provide coverage and pay for care.

Donald agreed that the dearth of innovation in the commercial insurance market has created opportunities for new business models to meet the cost and consumer service needs of employers and health plans. apree was formed by combining Vera Whole Health, an advanced primary care business, with Castlight Health, a digital care navigation platform. As Donald described it, the approach was validated by two early clients who also participated in the firm's cap table. "Elevance was our anchor client on the payer side and JP Morgan was our core client on the employer side. We started with JP Morgan in their Columbus market with 38,000 lives. After we built-out and deployed the product suite at a market level, we started to think about what it would like to do this on a multi-market basis."

Both Transcarent and apree are gaining significant traction with employers and consumers, proving that markets will reward diverse approaches that meet the need for value.

It was a powerful discussion to end another edition of the healthcare industry's premier private company healthcare conference.

Keith Hollihan is Editorial Director at 4sight Health.



M&A Activity

Selected Recent Healthcare Transactions (\$MM)

Selected i	Recent Healthcare Tra	iisactions (φινινί)		Enterpris	se Value /	
Date T	arget Name	Acquirer	EV	LTM Rev.	LTM EBITDA	Description
10/19/2024 T	hree Oaks Hospice (Petra Capital)	Martis Capital	\$150-\$160	NA	~13.5x	Texas based hospice provider
10/18/2024 C	Carebridge	Elevance Health	NA	NA	NA	Tennessee-based in-home healthcare coordinator
10/15/2024 D	DirectMed Imaging (NMS Capital)	Frazier Healthcare Partners	NA	NA	NA	Provider of aftermarket parts and component repairs for diagnostic imaging equipment
10/14/2024 E	Synesonics (Bain Capital, MVM Partners, Amzak Health Investors, Endeavour Vision, Kaiser Permanente Ventures and Runway Growth Capital)	Hologic	\$350	NA	NA	Minimally invasive solutions for women's health
10/11/2024	Curation Health (Echo Health /entures)	Reveleer (Oak HC/FT)	NA	NA	NA	Provider of clinical insights at the point of care
	eyemart Express (FFL Partners and eonard Green & Partners)	VSP Vision	NA	NA	NA	Local eye care provider with nearly 250 stores in 42 states
10/1/2024	ountainview at Gonda Westside Los Angeles Jewish Health)*	Senior Resource Group	NA	NA	NA	West Los Angeles based continuing care retirement community with 175 RCFE-licensed independent living and 24 assisted living / memory care units
10/1/2024 S	Skincure Oncology	H.I.G. Capital	NA	NA	NA	Comprehensive model for the delivery of Image- Guided Superficial Radiation Therapy
10/1/2024 S	Surescripts	TPG	NA	NA	NA	Health information network
10/1/2024 V	/isiQuate	Accel-KKR	NA	NA	NA	Provider of advanced revenue cycle analytics, Alpowered workflow, and automation
9/30/2024 S	Science Exchange	Waud Capital Partners	NA	NA	NA	Provider of life sciences procurement and supplier management SaaS solutions
9/27/2024 J	ubilee Clinical Research	Pinnacle Clinical Research (LongueVue Capital)	NA	NA	NA	Multi-therapeutic site clinical trial site organization
9/25/2024 N	lew CDMO Platform	Blue Wolf Capital Partners	NA	NA	NA	New platform would combine seven European sites acquired from Recipharm and additional facilities from Synerlab
9/23/2024 B	BIOVECTRA (H.I.G. Capital)	Agilent Technologies (NYSE: A)	\$925	NA	NA	Contract development and manufacturing organization of active pharmaceutical ingredients and intermediates
9/23/2024 L	akeview Health*	Bradford Health Services (Lee Equity Partners)	NA	NA	NA	Provider of detoxification, residential, partial hospitalization, and intensive outpatient treatment services for individuals with substance use disorders and co-occuring conditions
9/20/2024 Ir	ntegrated Oncology Network	Cardinal Health (NYSE: CAH)	\$1,115	NA	NA	Physician-led independent community oncology network
9/17/2024 T	rials24	SubjectWell (WindRose Health Investors)	NA	NA	NA	Provider of global digital patient recruitment solutions
9/16/2024 V	/IO Med Spa	Freeman Spogli	NA	NA	NA	Franchisor of full-service med spas
9/16/2024 V	/IO Med Spa	Freeman Spogli	NA	NA	NA	Franchisor of full-service med spas

Private Placement Activity

Selected Recent Healthcare Transactions (\$MM)

Date	Company	Investor(s)	Туре	Amount	Description
10/15/2024	Alchemy	"a16z" Bio + Health with participation from Earvin "Magic" Johnson, Sandberg Bernthal Venture Partners, Banc of California, Twine Ventures, Springbank and AlleyCorp	Seed	\$31	In-house pharmacy programs with a focus on serving clinics with large HIV and Hepatitis C patient populations
10/8/2024	Maven Clinic	StepStone Group (lead), General Catalyst, Sequoia, Oak HC/FT, Icon Ventures, Dragoneer Investment Group, and Lux	Series F	\$125	Virtual clinic for women's and family health
10/8/2024	Eleanor Health	General Catalyst (lead), Town Hall Ventures, Echo Health Ventures, Northpond Ventures, Rethink Impact and Emerson Collective	Series D	\$30	Outpatient addiction treatment provider
10/2/2024	Rippl	Kin Ventures (lead), ARCH Venture Partners, General Catalyst, GV, F-Prime, Mass General Brigham Ventures, 1843 Capital and JSL Health	Series A	\$23	Virtual dementia care
10/1/2024	Nym	PSG (lead), Google Ventures, Addition, Samsung Next and Dynamic Loop Capital	Growth	\$47	Autonomous medical coding
10/1/2024	StrataPT	Council Capital (lead)	Undisclosed	\$25	Billing-aware practice management platform for outpatient therapy clinics
9/25/2024	Zing Health	Health 2047 Capital Partners, CRG, and First Trust Capital Partners (lead investors), Newlight Partners, Town Hall Ventures, Health 2047, and Leavitt Equity Partners	Undisclosed	\$140	Medicare Advantage insurer
9/24/2024	Centivo	Cone Health Ventures and MemorialCare Innovation Fund (leads), B Capital, Cox Enterprises, F-Prime Capital, Ingleside Investors, Morgan Health, Trinity Capital and JPMorgan Chase	Equity and Debt	\$75	Primary care-centered health plan offers employers a replacement to traditional health insurance carriers
9/16/2024	Brisk Health	Undisclosed	Undisclosed	\$100	Integrated health care payer and provider empowering older adults to remain independent in their homes and communities
9/10/2024	Habitat Health	Town Hall Ventures, New Enterprise Associates, and Kaiser Permanente	Undisclosed	\$50	Integrated health care payer and provider empowering older adults to remain independent in their homes and communities
9/5/2024	Thatch	Index Ventures and General Catalyst (co-leads), SemperVirens, The General Partnership, Andreessen Horowitz (a16z), Avid Ventures	Series A	\$38	Personalized health benefits platform
9/4/2024	Vesta Healthcare	RA Capital (lead), Oak HC/FT, Chrysalis Ventures, CareCentrix/Walgreens, Nationwide, Kaiser Permanente Ventures, Lux Capital, Generator Ventures, Deerfield Management	Series C	\$65	Virtual care provider group for people with home care
8/13/2024	PayZen	NEA (lead), 7wireVentures, SignalFire, Viola Ventures, and others	Series B	Equity: \$32 Debt: \$200	Healthcare fintech company
7/31/2024	Spring Health	Generation Investment Management (lead), Kinnevik, William K Warren Foundation, RRE, and Northzone	Series E	\$100	Comprehensive mental health solution for employers and health plans
7/31/2024	WellBe Senior Medical	Excellus BlueCross BlueShield and Intermountain Ventures	Undisclosed	Undisclosed	Provider of home-based medical care
7/30/2024	Flo Health	General Atlantic	Series C	\$200	Women's health capp

Equity Capital Markets

Market Overview

- Equity issuance continued to slow in October due to quarterend, earnings blackout periods and the looming U.S. Presidential Election:
 - o Last week: 2 follow-ons; 1 convertible
- 3 IPOs are on the road this week in what looks to be the last opportunity for issuers to launch and be truly unaffected by the U.S. election on 11/5
 - Medical device maker Ceribell executed a successful IPO in early October raising \$207 MM in an upsized & 10x oversubscribed deal that priced at the top end of the range and finished its first day of trading +47%

ECM Activity (Last 4 Weeks & YoY)

	2024 -	Last 4 W	eeks	2023 - Last 4 Weeks				
	Vol (\$MM)	# Deals	% Share	Vol (\$MM)	# Deals	% Share		
IPO	3,726	10	28%	0	0	0%		
CONV	4,490	4	34%	2,588	3	42%		
FO	5,040	20	38%	3,510	14	58%		
Total	13,255	34	100%	6,098	17	100%		

	2	024 YTD		2023 YTD			
	Vol (\$MM)	# Deals	% Share	Vol (\$MM)	# Deals	% Share	
IPO	24,821	48	15%	10,664	20	9%	
CONV	50,202	72	30%	40,994	61	36%	
FO	93,343	275	55%	60,767	243	54%	
Total	168,366	395	100%	112,425	324	100%	

U.S. ECM Offerings (LTM; IPOs, Follow-ons & Converts)



IPO & Follow-on 1-Week Performance (LTM)



Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct

Most Recent Healthcare Initial Public Offerings (\$MM)

	Issuer Information				Deal Sizing				Pricing		Performance	
Pricing Date	Company	Sector	Ticker	Deal Value (\$MM)	Market Cap (\$MM)		% Primary	Offer Price	Final Range	1-Day	1-Week	
10/10/2024	Ceribell	Medical Products	CBLL	\$207.3	\$578.3	35.8%	100.0%	\$17.00	\$14.00 - \$16.00	47.1%	55.9%	
7/24/2024	Concentra Group Holdings	Services	CON	\$546.4	\$2,992.6	18.3%	100.0%	\$23.50	\$23.00 - \$26.00	(4.3%)	(0.8%)	
7/17/2024	Ardent Health Partners	Services	ARDT	\$220.8	\$2,255.4	9.8%	100.0%	\$16.00	\$20.00 - \$22.00	0.4%	4.7%	
6/13/2024	Tempus Al	Healthcare Technology	TEM	\$410.7	\$6,098.8	6.7%	100.0%	\$37.00	\$35.00 - \$37.00	8.8%	(26.3%)	
6/6/2024	Waystar Holding	Healthcare Technology	WAY	\$1,076.3	\$3,583.2	30.0%	100.0%	\$21.50	\$20.00 - \$23.00	(3.7%)	3.0%	

Most Recent Healthcare Follow-on Offerings (\$MM)

	Issuer Information					Deal Sizing				Perforn	nance
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value (\$MM)	Market Cap (\$MM)		% Primary	Discount to File	1-Day	1-Week
10/2/2024	Pennant Group	Services	Marketed	PNTG	\$124.8	\$1,097.8	11.4%	100.0%	(13.2%)	9.1%	9.4%
9/12/2024	GE HealthCare Technologies	Medical Products	Bought	GEHC	\$1,290.0	\$39,939.7	3.2%	0.0%	(1.7%)	1.1%	5.4%
9/6/2024	PACS Group	Services	Marketed	PACS	\$690.0	\$5,778.8	11.9%	16.8%	(8.3%)	2.3%	10.3%
9/4/2024	Sotera Health	Medical Products	Bought	SHC	\$381.3	\$4,364.3	8.7%	0.0%	(1.0%)	8.1%	6.2%
8/15/2024	Sonida Senior Living	Services	Marketed	SNDA	\$116.1	\$593.3	19.6%	100.0%	(15.6%)	(2.0%)	(1.9%)

Most Recent Healthcare Convertible Debt Offerings (\$MM)

	Issue	r Information				Pricing		
Pricing Date	Company	Sector	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	Coupon	Premium
5/23/2024	HAEMONETICS	Medical Products	HAE	\$700.0	\$4,580.3	15.3%	2.50%	30.00%
3/6/2024	Tandem Diabetes Care	Medical Products	TNDM	\$316.3	\$1,778.9	17.8%	1.50%	27.50%
3/4/2024	iRhythm Technologies	Medical Products	IRTC	\$661.3	\$3,378.2	19.6%	1.50%	35.00%
12/6/2023	Merit Medical Systems	Medical Products	MMSI	\$747.5	\$3,784.4	19.8%	3.00%	32.50%
12/5/2023	Evolent Health	Healthcare Technology	EVH	\$402.5	\$3,066.0	13.1%	3.50%	42.50%




Public Equity Market Activity & Indices

Equity Indices (as of October 18, 2024)

			Returns		
Index	Wk Open	Wk Close	52 Week	Weekly	
DJIA	42,864	43,276	29.5%	1.0%	
S&P 500	5,815	5,865	37.1%	0.9%	
NASDAQ	18,343	18,490	40.2%	0.8%	
Russell 2000	2,234	2,276	33.7%	1.9%	
NYSE Healthcare	27,618	27,448	9.0%	(0.6%)	

	Retu	ırns	
Cain Brothers Indicies	52 Week	Weekly	
Acute Care	71.6%	5.9%	
Alternate Site Services	37.9%	4.6%	
Diagnostics	27.0%	(1.4%)	
Distribution	12.6%	2.6%	
Healthcare IT	29.2%	2.6%	
Healthcare REITs	66.0%	4.9%	
Managed Care	(1.2%)	(6.2%)	
Medical Technology	31.1%	1.7%	
Outsourced Services	(3.4%)	1.1%	
Pharma Services	38.4%	2.6%	
Pharmacy	(20.9%)	(6.4%)	
Primary Care	(55.6%)	3.4%	
Post-Acute Care Services	37.3%	2.7%	
Post-Acute Care Facilities	39.4%	2.4%	

Cain Brothers Healthcare Indices (1YR Performance)



High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

 IG Bond primary market issuance saw eight deals price last week for a total of \$26.3 BN in issuance; October MTD total issuance sits at \$55.5 BN


High Yield

 The high yield new issue market saw a relatively slow week amid a holiday-shortened week and the ramp-up of the Q3 earnings season


Term Loan B Market

 New issue CLO volume has remained strong, with over \$60 BN more in issuance this year as opposed to last year at this point

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$BN)



New-Issue Clearing Yields¹ (\$MM)

D. H. Diversi	2024	2004	30-Day Rolling Average
Double-B Issuers	2Q24	3Q24	10/18/24
Ba1	S+219 / 7.5%	S+192 / 7.0%	S+200 / 6.9%
Ba2	S+236 / 7.5%	S+192 / 7.0%	S+185 / 6.7%
Ba3	S+238 / 7.7%	S+268 / 7.9%	S+281 / 7.8%
Single-B Issuers	2Q24	3Q24	30-Day Rolling Average
Siligie-D issuers	2024	3Q24	10/18/24
B1	S+313 / 8.6%	S+333 / 8/6%	S+368 / 8.6%
B2	S+373 / 9.1%	S+363 / 8.9%	S+394 / 8.9%
В3	S+392 / 9.4%	S+394 / 9.3%	S+374 / 8.7%

Most Recent Healthcare High-Grade Issuances (\$MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
9/17/2024	Universal Health Services Inc*	Sr Notes	\$500	Baa3/BBB-/BBB-	4.625%	10/15/2029	+120	20 bps
9/17/2024	Universal Health Services Inc*	Sr Notes	\$500	Baa3/BBB-/BBB-	5.050%	10/15/2034	+145	25 bps
9/16/2024	Laboratory Corp of America*	Sr Notes	\$650	Baa2/BBB/	4.350%	4/1/2030	+95	25 bps
9/16/2024	Laboratory Corp of America*	Sr Notes	\$500	Baa2/BBB/	4.550%	4/1/2032	+110	20 bps
9/16/2024	Laboratory Corp of America*	Sr Notes	\$850	Baa2/BBB/	4.800%	10/1/2034	+120	25 bps
9/16/2024	Novartis Capital Corp	Sr Notes	\$1,000	Aa3/AA-/	3.800%	9/18/2029	+45	30 bps
9/16/2024	Novartis Capital Corp	Sr Notes	\$850	Aa3/AA-/	4.000%	9/18/2031	+57	28 bps

Most Recent Healthcare High-Yield Issuances (\$MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
9/17/2024	HAH Group	Sr. Sec. Notes	\$675	B2/B-/NR	9.750%	10/1/2031	622 bps	9.50%-9.75%
9/11/2024	Perrigo	Sr. Notes	\$715	Ba3/B+/BB	6.125%	9/30/2032	258 bps	6.50% area
8/16/2024	Prime Healthcare*	Sr. Sec. Notes	\$1,500	B3/B-/B	9.375%	9/1/2029	556 bps	9.50% area

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

Date	Issuer	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	Yield
10/18/2024	MyEyeDr	Goldman Sachs Merchant Banking	B3 / B-	Refinancing	\$1,400	SOFR+350, 0% @ 100	8.259%
10/18/2024	Paradigm Outcomes	OMERS Capital Partners	B2 / B	Refinancing	\$698	SOFR+350, 0% @ 100	8.259%

Most Recent Healthcare Pro Rata Issuances (\$MM)


Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
9/30/2024	Emergent BioSolutions	Public	B3 / B-	Refinancing	\$100mm 5-year ABL Revolver	Leverage-based Grid SOFR+175-225	Min Fixed Charge Coverage: 1.0x Min Liquidity

Public Finance Market


Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note remained steady week-over-week, closing at 4.08% on Friday. 10-year MMD also remained steady week over week
- Healthcare Public Issuance has outpaced 2023. Year to date issuance is up 163% in 2024 vs 2023
- Muni bond funds Investors added \$1.7 BN and high yield funds gained \$36 MM for the week ended September 20

Weekly New Issue Volume (\$MM)




MMD & UST Yield Curve



Benchmark Yields

Tre	asury Yie	elds	MN	s	Ratio		
Yr	Yield	Δ (W/W)	Yr	Yr Yield		MMD/ UST	
2	3.95%	0 bps	2	2.47%	0 bps	63%	
10	4.08%	0 bps	10	2.78%	0 bps	68%	
30	4.38%	(1 bps)	30	3.66%	(3 bps)	84%	

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance										
Borrower/Enhancement	Par (000s)	State	Issuer	Tax Status	LT Ratings (M/S/F)	Final Mat.	Call, Put or Reprice*	Final Mat. Cpn.	YTW	YTM
Recent Pricings, Week of 10/14										
White Plains Hospital OG	500,000	NY	DASNY	TE	Baa3 / BBB- / NR	2054	2034(C)	5.50%	4.21%	4.84%
Montefiore Obligated Group	125,425	NY	DASNY	TE	Baa3 / BBB- / NR	2047	2034(C)	5.50%	4.33%	4.82%
El Paso County Hospital District	54,800	TX	EPCHD	TE	NR / NR / A-	2054	2034(C)	4.25%	4.42%	N/A
Exp. Pricings, Week of 10/21										
WoodBridge Healthcare, Inc.	180,000	PA	CWBFA	TE	NR / NR / NR	-	-	-	-	-
LifeBridge Health	117,015	MD	MHHEFA	TE	A1 / A+ / NR	-	-	-	-	-
Beaufort Memorial Hospital	112,000	SC	SCJEDA	TE	NR / BB / NR	-	-	-	-	-
Penick Village Project	74,805	NC	NCMCC	TE	NR / NR / NR	-	-	-	-	-
Wichita Senior Housing	17,300	KS	CWK	TE	Aaa / NR / NR	-	-	-	-	-

Relevant News

Mental Health Finds A New Home In Urgent Care Centers¹

Definitive Healthcare | October 16, 2024

Urgent care clinics first popped up in the 1970s as a solution for non-life-threatening emergencies. While it took decades for these centers to mature and fully integrate with the broader U.S. healthcare system, they have now become a trusted option for many, so much so that today, urgent care is sometimes seen as a "traditional" provider setting. Now, we're witnessing the rise of specialty urgent care clinics across the country, which are stepping in to tackle the growing need for behavioral health support. With about 8% of emergency department visits related to mental health issues and many ERs struggling to keep up, these specialized clinics are filling a gap for people in crisis, offering prompt assistance and critical referrals for ongoing care. As these behavioral health urgent care clinics continue to gain traction, they hold the promise of reshaping how we approach behavioral health care in this country.

Pressure On Congress To Reform Medicare Physician Fee Schedule, Prevent Reimbursement Cuts²

AMJC | October 17, 2024

The proposed 2025 Medicare Physician Fee Schedule would cut physician reimbursement by 2.8%, and now a bipartisan group of lawmakers is urging Congress to pass legislation to block the cut. The letter was signed by 233 members of the House and spearheaded by Reps Mariannette Miller-Meeks, MD (R, Iowa), and Jimmy Panetta (D, California). The American Medical Association (AMA) and the American College of Rheumatology (ACR) applauded the letter and the number of members of the House who signed on to the letter, which is addressed to House Speaker Mike Johnson (R, Louisiana) and Minority Leader Hakeem Jeffries (D, New York). The letter urges Johnson and Jeffries to "expeditiously pass legislative fixes that not only stop another damaging round of cuts to Medicare payments, but also provide greater certainty and stability for clinicians serving Medicare beneficiaries."

Can Primary Care Thrive Outside Of Traditional Healthcare Players?³

MedCity News | October 22, 2024

The past couple of years have been rocky for companies looking to disrupt the traditional primary care model — with top retailers Walmart and Walgreens announcing that they're winding down their primary care operations significantly. Others still stand, though the jury is out on whether they can master the tough unit economics that come along with healthcare delivery. Recent failures in the retail health space beg the question: Is primary care only suited to remain within traditional players, such as health systems, physician practices and large employers? Four healthcare executives shared their responses to this question during a Sunday panel at HLTH in Las Vegas. The answer depends on how you define primary care, according to Nolan Chang, executive vice president of strategy, corporate development and finance for The Permanente Federation.

continued...

The Hospice CARE Act's Potential To 'Dramatically Reshape' End-Of-Life Care Delivery¹ Hospice News | October 15, 2024

Hospice providers and stakeholders are carefully examining the proposed changes included in the recently introduced Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act as the bill begins its journey through the legislative process. Leading concerns in the industry include the bill's suggested regulatory reforms to address program integrity in the hospice industry, along with potential changes to reimbursement, caregiver support and palliative care payment pathways. The Hospice CARE Act has a "long road ahead" before enactment, but its introduction presents both significant challenges and opportunities for hospice providers, said Ethan McChesney, policy director at the National Partnership for Healthcare and Hospice Innovation (NPHI).

Most Independent Pharmacies May Not Carry Negotiated Medicare Part D Drugs²

Healthcare Finance | October 21, 2024

A new national survey shows more than 90% of independent pharmacists may not sell drugs for which the Medicare Part D program is trying to negotiate lower prices. If they don't, the administration's effort to reduce prescription drug prices is bound to fail, according to the National Community Pharmacists Association. The administration announced in August a list of 10 drugs for which the Medicare Part D program will seek to negotiate lower prices. They include drugs for diabetes, blood clots, heart disease and other conditions. The drugs subject to the new pricing include Januvia, Farxiga, Enbrel, Jardiance, Setalara, Xarelto, Eliquis, Entresto, Imbruvica, and the Fiasp, or NovoLog FlexPen. The new prices are set to go into effect for people with Medicare Part D prescription drug coverage beginning January 1, 2026. According to the survey, 51% of respondents say they are strongly considering not stocking the drugs because of the potential underwater reimbursements from pharmacy benefit managers. (Underwater reimbursement is when a pharmacy is paid less than the cost of acquiring a drug.) Another 40% of respondents say they are somewhat considering not stocking the medications.

Telehealth Is 'Where The Puck Is Going' In Youth Behavioral Health³

Behavioral Health Business | October 11, 2024

Outpatient youth behavioral health services will likely continue to attract interest from venture capital, especially services that are enabled by telehealth and AI. That was one takeaway from a panel regarding the future of youth behavioral health models, which was part of Behavioral Health Business's INVEST conference held in Dallas. Jose Guerola, a principal at Echo Health Ventures, said outpatient services "is where the puck is going" when it comes to investment Echo and other venture firms give to youth-focused behavioral health companies. Meanwhile, residential treatment "is just not a focus for us right now," Guerola said. The heightened interest in outpatient settings enabled by telehealth and the waning interest in residential services are driven by several potent trends. On one hand, telehealth is seen as a way to overcome care access challenges. Investors have thus piled into this segment. Guerola noted that Echo, which is based in Durham, North Carolina, has made equity offerings to companies such as Eleanor Health, which provides "addiction treatment from the comfort of home."

Recent Cain Brothers Transactions

October 2024

USFertility

a portfolio company of



\$635,000,000

Senior Secured Credit Facilities

Left Lead Arranger, Joint Bookrunner & Administrative Agent

September 2024



has formed a strategic partnership with



Financial Advisor

Pending



a subsidiary of



has agreed to be acquired by



Financial Advisor

April 2024



\$800,000,000

9.750% Senior Secured Notes due 2029

Joint Bookrunner

October 2024

MultiCare 🛵

has completed an affiliation agreement with

OVERLAKE | MEDICAL CENTER & CLINICS

Buy-Side Advisor

September 2024



has acquired



Buy-Side Advisor

June 2024



has been acquired by



Sell-Side Advisor

April 2024





\$30,685,000 FHA 232/223(f) Refinancing

Mortgage Banking Advisor

September 2024



has been acquired by



Sell-Side Advisor

September 2024



Senior Secured Credit Facilities

provided by

Capital Markets

Pending



has agreed to be acquired by



Sell-Side Advisor

April 2024



\$116,000,000

Senior Secured Credit Facilities

Lead Left Arranger, Sole Bookrunner & Administrative Agent

Pending



Indiana University Health

has agreed to sell its health plan business to



Sell-Side Advisor

August 2024



\$33,785,000

Adjustable-Rate Hospital Revenue Refunding Bonds (Tax Exempt)

Sole Manager

June 2024



has transferred its Managed Long Term Care Members



Sell-Side Advisor

April 2024



\$108,295,000

Fixed Rate Bonds

Sole Manager

Senior Investment Banking Team



Wyatt Ritchie (415) 450-7856 writchie@cainbrothers.com **Group Head**

Health Tech



Jill Frew (212) 981-6916 jfrew@cainbrothers.com Digital Health, B2C / Payer

Life Sciences



Carl Hardie (718) 887-6221 chardie@cainbrothers.com **Outsourced Medical** Manufacturing & Service Providers



Lee Sophocleous (212) 476-7438 Isophocleous@cainbrothers.com



John Kerins (212) 981-6891 jkerins@cainbrothers.com Pharma Services / Pharma Tech-**Enabled Services**

Sean Trail

(312) 360-3883

Manufacturing

strail@cainbrothers.com

Dental Devices / Contract



Roman Rezanowicz (212) 981-6928 rrezanowicz@cainbrothers.com Pharma Services







Mike Elizondo (415) 962-2951 melizondo@cainbrothers.com Managed Care / Care Coordination



Stacy Guffanti (212) 981-6925 sguffanti@cainbrothers.com Managed Care / Women's Health



Court Houseworth (415) 962-2956 chouseworth@cainbrothers.com Managed Care / Specialty Health

Providers



Patrick Allen (630) 542-8734 pallen@cainbrothers.com Multi-Site Providers / Physician Groups / Practice Management



David Cohen (212) 297-2723 dcohen@cainbrothers.com Hospitals & Health Systems



Dan Gold (847) 219-6670 dgold@cainbrothers.com Primary Care / Value-based Care



Andy Goldberg (212) 981-6898 agoldberg@cainbrothers.com Outsourcing / Staffing / Distribution



Erika Haanpaa (212) 297-2754 ehaanpaa@cainbrothers.com Behavioral Health



Andy Labovitz (212) 981-6940 alabovitz@cainbrothers.com Hospitals & Health Systems



Matthew Margulies (212) 981-6938 mmargulies@cainbrothers.com Home Health & Hospice / Distribution / Pharmacy



Jim Moloney (415) 962-2961 jmoloney@cainbrothers.com Hospitals & Health Systems / Physician Groups



David Morlock (312) 604-0575 dmorlock@cainbrothers.com Hospitals & Health Systems / **Primary Care**



Todd Rudsenske (617) 385-6265 trudsenske@cainbrothers.com Behavioral Health



Jonah Schutzman (212) 476-7445 jschutzman@cainbrothers.com Physician Practice Management



Jenny Watson (216) 689-7701 jwatson@cainbrothers.com Dental / Health & Beauty

Healthcare Product Partners



Steve Alcauskas (503) 821-3999 steven.alcauskas@key.com Lending / Banking Products



Carl McCarden (646) 279-7621 cmccarden@key.com Sponsor Coverage



Ryan Stilphen (440) 915-6687 ryan.stilphen@key.com Leveraged Finance



Mark Barath (216) 689-4747 mbarath@key.com **Equity Capital Markets**



Senior Public Finance Team



Zach Kau (415) 486-3422 zach.kau@key.com



Kyle Hemminger (614) 460-3448 khemminger@cainbrothers.com



Dominic Porretta (212) 981-6955 dporretta@cainbrothers.com



Bart Plank (212) 981-6915 bplank@cainbrothers.com



Kathy Kirchhoff (562) 264-0300 kkirchhoff@cainbrothers.com



Taaha Shaikh (212) 981-6903 tshaikh@cainbrothers.com



James Conahan (212) 981-6893 jconahan@cainbrothers.com



Joe Mulligan (314) 800-0441 jmulligan@cainbrothers.com



Joanna Stephenson (646) 205-0276 jstephenson@cainbrothers.com



Maura Davalos (716) 819-5354 mdavalos@cainbrothers.com



Joe Pollock (415) 962-2957 jpollock@cainbrothers.com



Chris Whitley (805) 302-3293 cwhitley@cainbrothers.com

Industry Insights is compiled weekly by Cain Brothers, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019 Ph: (212) 869-5600. To receive our Industry Insights email, please register on www.cainbrothers.com. For questions regarding Industry Insights please email rgruber@cainbrothers.com

The information contained in this report was obtained from various sources, including third parties, that we believe to be reliable, but neither we nor such third parties guarantee its accuracy or completeness. Additional information is available upon request. The information and opinions contained in this report speak only as of the date of this report and are subject to change without notice. This report has been prepared and circulated for general information only and presents the authors' views of general market and economic conditions and specific industries and/or sectors. This report is not intended to and does not provide a recommendation with respect to any security. Cain Brothers, a division of KeyBanc Capital Markets ("Cain Brothers"), as well as any third-party information providers, expressly disclaim any and all liability in connection with any use of this report or the information contained therein. Any discussion of particular topics is not meant to be comprehensive and may be subject to change. This report does not take into account the financial position or particular needs or investment objectives of any individual or entity. The investment strategies, if any, discussed in this report may not be suitable for all investors. This report does not constitute an offer, or a solicitation of an offer to buy or sell any securities or other financial instruments, including any securities mentioned in this report. Nothing in this report constitutes or should be construed to be accounting, tax, investment or legal advice. Neither this report, nor any portions thereof, may be reproduced or redistributed by any person for any purpose without the written consent of Cain Brothers and, if applicable, the written consent of any third-party information provider.

"Cain Brothers, a division of KeyBanc Capital Markets" is a trade name of KeyBanc Capital Markets Inc. Member FINRA/SIPC.

KeyBanc Capital Markets Inc. and KeyBank National Association are separate but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank National Association. Credit products are subject to credit approval. Copyright © 2024 KeyCorp.

